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Abstract
Animal African trypanosomiasis (AAT) is a significant socioeconomic burden for sub-Saharan Africa 
due to its huge impact on livestock health. Existing therapies including those based upon Minor 
Groove Binders (MGBs), such as the diamidines, which have been used for decades, have now lost 
efficacy in some places due to the emergence of resistant parasites. Consequently, the need for new 
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chemotherapies is urgent. Here, we describe a structurally distinct class of MGBs, Strathclyde MGBs 
(S-MGBs), which display excellent in vitro activities against the principal causative organisms of 
AAT, Trypanosoma congolense and T. vivax. We also show the cure of T. congolense-infected mice 
by a number of these compounds. In particular, we identify S-MGB-234, compound 7, as curative 
using 2 applications of 50 mg/kg intraperitoneally. Crucially, we demonstrate that S-MGBs do not 
show cross-resistance with the current diamidine drugs and are not internalised via the transporters 
used by diamidines. This study demonstrates that S-MGBs have significant potential as novel 
therapeutic agents for animal African trypanosomiasis. 
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Introduction
African animal trypanosomiasis (AAT), or nagana, is a major obstacle to livestock production and, 
therefore, to the development of rural areas of sub-Saharan Africa. AAT is a complex of diseases 
mainly caused by three tsetse-transmissible trypanosome species: Trypanosoma congolense, T. vivax 
and, to a lesser extent, T. brucei spp. Although all domesticated animals can be infected by 
trypanosomes, cattle are the main economically and clinically relevant host (1). Most AAT cases are 
chronic, with animals presenting with anaemia, weight loss, weakness, immunosuppression, sterility 
and decrease in milk production. Death of susceptible animals is a common outcome. Thus, AAT 
significantly limits agricultural development and food production and, consequently, socioeconomic 
growth. It is a considerable cause of poverty in African rural communities, with total losses estimated 
at US$ 4.75 billion per year (2).
Control of AAT relies heavily on chemotherapy or chemoprophylaxis (3). Only two compounds are 
widely used, irrespective of the infecting species (Fig. 1): diminazene diaceturate, 1, a diamidine and 
DNA minor groove binder used for cure, and isometamidium chloride, 2, a hybrid molecule of 
ethidium and diminazene used for both cure and prophylaxis. In addition, the DNA intercalator 
ethidium bromide, 3, is available for treatment and also gives some short-term prophylaxis (3). All 
these compounds have toxic effects on animals and their efficacy is undermined by increasing drug 
resistance (4-8). Despite the high usage levels (at least 35 million doses/year), pharmaceutical 
companies are disengaged from this area due to the lack of commercial incentive. Consequently, since 
the introduction of diminazene and isometamidium more than 50 years ago, no progress has been 
made towards new AAT chemotherapy. However, a renewed interest in alternative veterinary 
trypanocides has emerged due to the disease's impact on food security, and the engagement of a 
Product Development partnership, the Global Alliance for Livestock Veterinary Medicines 
(GALVmed), has provided new coordination in tackling the problem.
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Figure 1. Chemical structures of the three main compounds used for treatment and prophylaxis of 
AAT and of the arylamidines pentamidine, DB75 and DB289.
Minor groove binders (MGBs) comprise several classes of compounds that bind to the minor 
groove of DNA and have been used as therapies for both human and animal infections (9-11). 
Diminazene, 1, is an example of the diamidine class of MGBs, which also includes pentamidine, 4, 
(Fig. 1), a compound with a broad antimicrobial activity (11). Pentamidine has been used most 
notably as a treatment for human African trypanosomiasis (HAT); however, it suffers from toxicity 
issues and poor oral availability, requiring parenteral administration for systemic infections (11). The 
di-arylamidines were used as the basis of a synthesis campaign by Boykin and co-workers, which led 
to the discovery of DB75, 5, (furamidine, Fig. 1), a highly active antitrypanosomal drug in animal 
studies, and its orally available prodrug DB289, 6, (pafuramidine, Fig. 1) (12, 13). Pafuramidine, 6, 
concluded Phase II/III clinical trials against early-stage HAT before renal toxicity in a retrospective 
phase I safety trial led to its development being discontinued (14). Yet, this trial once again 
underscored the clinical efficacy of MGBs (with the toxicity attributable to the pro-drug strategy (14), 
and the enormous impact of diminazene and pentamidine as the most essential trypanocides to date 
serves as a reminder of the potential of MGBs as antiparasitic therapies (11). Crucially, cross-
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resistance with existing diamidine drugs does not occur if the diamidine transport mechanisms are 
avoided (15).
Strathclyde minor groove binders (S-MGBs) are a distinct family of DNA-binding compounds 
derived from the structure of the natural product distamycin (16). S-MGBs include a diverse array of 
structural features allowing for extensive coverage of structural and property space within the same 
DNA-binding template (17). The main sites where variation is introduced in S-MGBs are the head 
groups and the specific linker moiety used to connect to the rest of the molecule (amidine, amide or 
alkene), the particular heterocycle, the alkyl substituents on the heterocycle, and the basicity of the C-
terminal tail group (18). Through altering these structural features, potent antibacterial compounds 
have been discovered, one of which, MGB-BP-3, is about to enter a Phase IIa clinical trial against 
Clostridium difficile infections (19). A variety of MGB-BP-3 analogues have been shown to be active 
against T. brucei and Plasmodium falciparum (20, 21), both in cell-based studies and in in vivo 
disease models, and against Leishmania major and L. donovani in culture (unpublished results). A 
potential benefit of targeting DNA is that it is to be expected that many binding sites will be occupied 
by S-MGBs, leading to complex cellular perturbations, which could mitigate the risk of rapidly 
developing resistance. Conversely, the ubiquity of DNA makes species selectivity critical and this has 
been a challenge for some previous generations of MGBs. In the context of S-MGBs, selectivity can 
be obtained between different infectious organisms and mammalian cells giving rise to therapeutic 
ratios indicative of selective drug candidates (16 - 19, 22).
In this paper we describe the activity of S-MGBs against the animal infective parasites T. 
congolense and T. vivax, from which an initial SAR was developed. Three S-MGBs were advanced to 
in vivo proof of concept evaluation in a mouse model of T. congolense infection. Two of these were 
curative and, crucially, displayed no cross-resistance with currently used trypanocides. Furthermore, 
we present the results of an initial investigation into the mechanism of action of the lead compound, 
S-MGB-234, 7.
Results
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Structure-activity relationship revealed. A substantial and representative collection of S-MGBs was 
screened for activity against T. congolense and T. vivax, and in parallel against L6 rat myoblast cells 
as an indicator for mammalian cell toxicity. S-MGBs were selected in order for the collection to 
explore a large chemical space from our entire S-MGB library. Those compounds of interest to SAR 
discussions are presented in Table 1 (full data set in Table S1). Most of the compounds studied have 
been previously described (16, 17, 18, 21), but several are novel. Details of the synthesis of novel 
compounds from Table 1 are outlined in Scheme 1 below. Briefly, the appropriate nitro pyrrole dimer 
was converted to the corresponding amine by reduction with hydrogen gas over palladium on carbon. 
This amine was then coupled to the appropriate carboxylic acid using HBTU to form the final S-
MGB. Syntheses of the specific nitro pyrrole dimers and carboxylic acids have been previously 
reported, and are referenced in the experimental section.
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Scheme 1. Synthesis of novel MGBs from Table 1. (i) H2, Pd/C, MeOH, not isolated (ii) Carboxylic 
acid, HBTU, DMF.
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The full data set presented in Table S1 identify several structural features that appear to improve 
activity against T. congolense and/or T. vivax. The following discussion summarises the principal 
observations, with Table 1 summarising the activities and structures of the compounds of interest, but 
Table S1 should be referred to for the full data set. 
Table 1. Activity of a collection of S-MGBs against T. congolense, T. vivax and L6 cells
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0.06±0.02 0.02±0.01 0.04±0.01 0.7 1.9
Data are reported as a mean of 3 experiments ± standard deviation, reported to two decimal places; SI, 
selectivity index calculated by division of the indicated mean values, reported to one decimal place.
Several compounds displayed EC50 values against T. congolense below 100 nM (15, 8, 7) and two of 
these contained the 3-quinolylalkenyl head group. Against T. vivax, compounds active at 100 nM or 
less also contained the 3-quinolylalkenyl head group (14, 15, 11). Indeed, alkenyl head groups, 
especially those containing the 3-quinolyl group, led to the strongest activity against both species; 
other aryl alkenes and related fused heterocyclic alkenes were in general much more weakly active. 
Although some 3-quinolyl alkenes were toxic to rat L6 cells, the selectivity index (SI) of one of these 
(11) was >30 fold. The structure of the tail group also affected the differential activity. Both the 
amidinylethyl and dimethylaminoethyl/propyl series included active compounds with very good SI 
values, especially relative to T. congolense (7, 8, 11). Further, as shown by the L6 cell-based assay, 
the effect of a number of substructures on cytotoxicity could be identified. Compounds that contained 
amidine-linked head groups, trifluoromethylphenyl, or benzoxazole head groups, or long side chains 
were predominantly inactive In general, compounds containing amide-linked head groups were poorly 
active as well as non-toxic to L6 cells (Table S1). However, bearing in mind the variations in 
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trypanocidal activity of amidine- and alkene-containing head groups, it may simply be that active 
amide head groups have not yet been identified. On the basis of their intrinsic antitrypanosomal 
activity and favourable SIs, a small subset of S-MGBs (7, 8 and 11) was selected for further in vitro 
evaluation, along with some additional compounds for comparison purposes (12, 13, 9 and 10). 
Absence of cross-resistance to diamidines. As noted above, the diamidine class of MGBs, which has 
been in use for over 60 years against trypanosomiasis, has suffered from the emergence of resistance 
by the parasites (23 - 25). It was important, therefore, to establish whether the S-MGBs here identified 
as trypanotoxic retained activity in diamidine-resistant trypanosomes. To assess this, a small subset of 
S-MGBs from the initial screen, including the most therapeutically relevant, was tested against two 
diminazene-resistant T. congolense lines generated in vitro. Our results revealed no decrease in 
activity of the S-MGBs against the diminazene-resistant lines, which instead showed a modest but 
significant hypersensitivity to some of the compounds (Fig. 2a and Table S2 for all data).
In T. brucei, resistance to diamidines including diminazene and furamidine is linked to loss of activity 
of specific plasma membrane transporters TbAT1/P2 (26-28) and, in the case of pentamidine, also of 
HAPT/AQP2 (29, 30), that mediate their uptake into this parasite. TbAT1/P2 impairment also causes 
cross-resistance to compounds which contain the same TbAT1/P2 recognition motifs, including the 
melaminophenyl arsenicals melarsoprol and cymelarsan (26, 31). In order to determine the potential 
for cross-resistance developing as a result of sharing the same route of cellular entry, the S-MGBs 
were evaluated as substrates for these known MGB transporters. The same subset of compounds listed 
above was tested against T. b. brucei lines lacking only TbAT1/P2 (tbat1-/- line (26)) or both 
TbAT1/P2 and HAPT/AQP2 (B48 line (29). The experiments showed that trypanosomes not 
expressing these drug transporters, and therefore resistant to diminazene, generally retained sensitivity 
to the S-MGBs (Fig. 2b and Table S3 for all data), with only a minor increase in EC50 (1.5 fold) for 9 
against the tbat1-/- and B48 lines and for 7 against the B48 line. These data confirmed that the activity 
of S-MGBs is not (principally) dependent on the expression of T. brucei TbAT1/P2 or HAPT/AQP2 
and that the S-MGBs are not cross-resistant with current diamidines. This is an important further 
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indication of the differences between S-MGBs and other classes of MGBs such as the diamidines. Of 
note, T. congolense lacks a functional equivalent of TbAT1/P2 (32), and HAPT/AQP2 (unpublished 
data), although other T. brucei group trypanosomes (incl. T. equiperdum, T. evansi, T. b. gambiense, 
T. b. rhodesiense (33-36)) most likely do. We conclude that diamidines and S-MGBs must enter via 
other, as yet unidentified, routes in T. congolense and, based on the absence of cross-resistance 
(Figure 2 and Tables S2 and S3), that S-MGBs do not share uptake routes with diamidines in either T. 
brucei or T. congolense.
Figure 2. S-MGBs retain trypanocidal activity in vitro against diminazene-resistant T. congolense and 
T. b. brucei lines. a T. congolense diminazene-resistant lines DimR and EMS MUT DimR. The EC50 
values against T. congolense presented in this figure were obtained using a different protocol from 
that of the initial compound screen (data in Table 1 and Table S1), hence the difference in absolute 
values between the two datasets. b T. b. brucei tbat1-/- lacks the P2 amino-purine transporter 
TbAT1/P2 (26) and line B48 lacks both TbAT1 and HAPT/AQP2 activity (29). (Mean ± SEM, n≥3). 
Statistical significance to untreated wild type (WT) line was assessed by unpaired t-test: * p<0.05; ** 
p<0.01; **** p<0.0001.
Page 10 of 51
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
In vivo efficacy of S-MGBs in an experimental model of T. congolense infection. Compounds 7, 8 
and 11 were further progressed for in vivo efficacy studies in a mouse model of infection with T. 
congolense STIB 736/IL1180. Mice were infected intraperitoneally (i.p.) with T. congolense and 
parasitaemia was allowed to develop before treatment with the three selected compounds. At the end 
of a 2-month monitoring period, aparasitaemic mice were considered cured (37). The therapeutic 
effect of each compound is shown in Table 2.
Table 2. In vivo efficacy of selected S-MGBs in the T. congolense (STIB 736/IL1180) experimental 
mouse model of infection.
S-MGB-ID
Dose
(mg/kg/day × number 
of treatment days)
Cured/
infected
MRD
(days)
MSD
(days)
7a 50 × 4 toxic n/a n/a
50 × 2 4/4 n/a >60
10 × 4 1/4 19.3 34.75
10 × 2 0/4 12.5 19.5
8a 50 × 4 toxic n/a n/a
50 × 2 toxic n/a n/a
10 × 4 4/4 n/a >60
10 × 2 4/4 n/a >60
10 × 1 3/4 7 >51
5 × 2 3/4 4 >50.25
11a 50 × 4 toxic n/a n/a
50 × 2 1/4 11 >29.25
10 × 4 0/4 5.5 15
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10 × 2 0/4 4 11
Untreated n/a 0/4 n/a 11
a Vehicle 10% DMSO in water solution; MRD, mean day of relapse; MSD, mean day of survival; n/a, 
not applicable.
7 provided total cure and no relapses in mice (4/4), when treated with 2 applications of 50 mg/kg i.p. 
Partial cure (1/4) was seen in mice treated with 4 daily applications of 10 mg/kg i.p., whilst only 2 
applications of 7 at 10 mg/kg i.p. gave no cure but prolonged survival relative to the untreated control.
8 was fully curative (4/4) when administered as either 4 or 2 applications at the lower dose of 10 
mg/kg i.p. At a total dose of 10 mg/kg, given as a single treatment i.p., or as 2 applications of 5 mg/kg 
i.p. 24 hours apart, a similar curative efficacy (3/4) was seen for both administrative regimens. 
Only a partial cure (1/4) was achieved with 11 in mice treated with 2 applications of 50 mg/kg i.p., 
with average relapse and survival days of 11 and >29.25, respectively. No cure was seen at 10 mg/kg 
i.p., at either 2 or 4 daily administrations, with marginal effects on survival. Full cure with 11, e. g. at 
50 × 4 mg/kg was attempted but could not be achieved due to apparent toxicity at the higher dosages. 
These data show efficacious treatment of a T. congolense mouse model of infection for two out of 
three S-MGBs at non-toxic dosage regimens. Although 8 performed slightly better in the T. 
congolense mouse model of infection, 7 was selected as our lead compound for further investigative 
studies due to its higher activity in the in vitro T. vivax assay, together with two fluorescent S-MGBs 
with less activity. 
Intracellular distribution into trypanosomes. The intrinsic fluorescence of some S-MGBs makes it 
possible to investigate their intracellular distribution in trypanosomes following incubation. As 
previously shown for T. b. brucei (21), experiments with the highly fluorescent 9 confirmed 
internalisation in T. congolense (Fig. 3a). The main visible cellular targets, clearly detectable using 
the FITC filter, were the nucleic acids (nucleus and kinetoplast), as expected for these MGBs, many 
of which have been shown to bind strongly to AT sites of DNA by footprinting and biophysical 
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methods (22). DAPI colocalisation with both 9 and another fluorescent S-MGB, 16, confirmed 
organelle identification, and showed that DAPI staining of the kinetoplast abolished S-MGBs 
fluorescence in this organelle (Fig. S1). Despite thorough washing of T. brucei labelled with 16 and 9, 
the fluorophores were retained in both DNA-containing organelles (data not shown). Together with 
the main fluorescent emission observed under the green channel, 9 (and the other fluorescent S-
MGBs) also emitted at longer wavelength, labelling other subcellular structures visible under DsRed 
filter. In particular, a bright vesicle posterior to the nucleus was clearly visible under the DsRed filter. 
The accumulation of S-MGBs in organelles other than the nucleus and kinetoplast adds complications 
to the understanding of their mechanism of action. Binding to the DNA double helix or interference 
with DNA-protein interactions are obvious targets for S-MGBs but there may be others as yet 
unidentified. 
Metabolomics analysis. An untargeted metabolomics analysis was performed using 7 to assess the 
effects of S-MGBs on the metabolism of T. b. brucei (Fig. 3b). Results showed an accumulation of 15 
putatively identified metabolites (p <0.05, >2 fold change) in treated parasites (Fig. 3b and Table S4), 
with a preponderance of metabolites involved in nucleotide metabolism, particularly pyrimidine 
metabolism. Among these, the pyrimidine nucleoside deoxyuridine showed the largest increase (> 7 
fold compared to DMSO control), followed by other pyrimidines: cytosine, cytidine, dCTP, uridine, 
dUMP, dAMP and dihydrouridine. The accumulation of the purine derivative hypoxanthine was also 
recorded.
Among the other putative metabolites emerging from the analysis, creatinine is believed to be 
irrelevant to trypanosome metabolism and probably accumulated from serum present in the medium.  
The observed changes in levels of various cofactors (including pyridoxine, pyridoxamine, 
dethiobiotin) are intriguing, but so far their significance remains elusive. 
Taken together, the metabolomics data seems to indicate that the S-MGBs interfere with the integrity 
and /or functions of nucleic acids, with the most notable perturbations in nucleotide metabolism, 
while most of the metabolome remained unaffected following 8 hours of treatment,.
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Figure 3. S-MGBs target the nucleic acids in trypanosomes. a Accumulation and intracellular 
distribution of highly fluorescent 9 (incubation with 2 × EC50 for 2 h or 48 h) in T. congolense. N, 
nucleus; K, kinetoplast; arrow = other stained subcellular structures. Bar = 10 µm. b Volcano plot of 
metabolic changes in T. b. brucei following treatment with 7 (5×EC50, 8 hours). The time point was 
chosen based on 7 growth inhibition curve (Fig. 5a), allowing time for metabolic perturbations to 
emerge but avoiding cidal effects on cells. Red dots indicate putative metabolites significantly up-
regulated as compared to untreated DMSO control; blue dots indicate metabolites significantly down-
regulated as compared to control. Differentially abundant metabolites were identified by p <0.05 (t-
test) statistical significance and 2 fold-change cut-off. 1) 5-6-Dihydrouridine; 2) Creatinine; 3) 
Cytidine; 4) Cytosine; 5) dAMP; 6) dCTP; 7) Deoxyuridine; 8) Dethiobiotin; 9) L-Lysine; 10) dUMP; 
11) Hypoxanthine; 12) N6-Acetyl-L-lysine; 13) NG,NG-Dimethyl-L-arginine; 14) Pyridoxine; 15) 
Uridine; 16) Pyridoxamine.
Mitochondrial DNA is not the main S-MGB target. The kinetoplast (trypanosome mitochondrial 
DNA) has long being considered as the main subcellular target of diamidines, phenanthridines and 
other cationic MGBs and intercalators. Upon binding to AT-rich sites in the minor groove, diamidines 
cause inhibition of replication of the kDNA and its disintegration, with consequent cell death (11). 
Trypanosomes can adapt to survive without a (complete) mitochondrial genome, as do T. evansi and 
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T. equiperdum, but it was found that the viability of such cells depends on a compensating mutation in 
a nuclear-encoded F1Fo ATPase subunit, which allows mitochondrial membrane potential to be 
maintained (38). These akinetoplastic parasites are less sensitive to diamidines than trypanosomes 
depending on an intact kinetoplast and are also more resistant to the phenanthridine class of drugs, 
which also target nucleic acids (39, 40). To assess whether the presence of a functional kinetoplast 
was equally important for the action of our S-MGBs, 7 was tested against a T. b. brucei line (ISMR1) 
where the kinetoplast has been lost following in vitro selection for resistance to the phenanthridine 
isometamidium chloride (39). 7 was equally active against the akinetoplastic line ISMR1 and the wild 
type line that possesses a normal kinetoplast (Fig. 4, Table S5). These results were confirmed by tests 
on a kinetoplast-independent T. b. brucei line engineered to express an F1 ATPase subunit with 
mutation L262P (40), which rapidly loses its normal kinetoplast under kinetoplast-targeting drug 
pressure because it is no longer dependent on it (Table S5). 7 activity was comparable across all these 
lines, suggesting that its trypanocidal activity is independent from the presence of a functional 
kinetoplast. These data are in sharp contrast to those obtained for the diamidine diminazene and the 
phenanthridines isometamidium and ethidium, to which the akinetoplastic cell lines are highly 
resistant (39, 40). Importantly, these data seem to preclude the emergence of cross-resistance between 
S-MGBs and the phenanthridine trypanocides (isometamidium chloride and ethidium bromide) 
currently used against AAT as the sole alternatives to diminazene aceturate.
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Figure 4. The kinetoplast is not required for S-MGBs trypanocidal activity. The EC50 value of 7 did 
not significantly change when the compound was tested against T. b. brucei ISMR1, an akinetoplastic 
line selected in vitro for resistance to isometamidium and highly cross-resistant to ethidium bromide 
and to diminazene. 
S-MGBs affect trypanosome growth and cell cycle progression. Continuous exposure to 7 resulted 
in cell growth arrest of T. b. brucei cultures within 48 h when incubated with concentrations ≥1 × 
EC50 (i.e. 0.16 µM), with complete clearance at 10 × EC50 (Fig. 5a, left). Similarly, 5 × EC50 of 7 
(2.55 µM), sterilised T. congolense cultures within 72 h, or after 96 h at 2 × EC50  (Fig. 5a right). 
Wash-out experiments showed that 7 has irreversible effects on trypanosome survival, indicating that 
this compound is cytocidal and not cytostatic (Table S6). Treated T. congolense were committed to 
death after 10 – 24 h of incubation with 7 at 5 × EC50. In order to produce irreversible effects on T. 
brucei survival, higher concentrations of the compounds had to be used: exposure to 10 × EC50 for 10 
h committed all parasites to death, possibly reflecting the need for a higher concentration gradient to 
achieve a lethal concentration at the intracellular site of action within this time frame. These kinetics 
and concentrations were comparable to those obtained for the slow acting veterinary drug diminazene 
(Table S6).
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An analysis of the cell cycle progression of trypanosomes exposed to 7 was performed by monitoring 
the replication and segregation of the nuclear (N) and kinetoplast (K) genomes, which in these 
parasites occur in sequential, tightly regulated phases (41). This process is similar in T. brucei and T. 
congolense, but for our analysis we used only the former due to the tendency of T. congolense to 
clump together in vitro, making it difficult to distinguish individual cells.
DNA analysis of asynchronous T. b. brucei populations treated with 7 revealed a profound effect of 
the compound on normal cell cycle progression (Fig. 5b). 7 caused an accumulation of parasites with 
multiple kinetoplasts and nuclei (MKMN cells), seemingly cells that have started a new cell cycle 
without having undergone cytokinesis. At 48 h of treatment with 2 × EC50, the MKMN trypanosomes 
constituted more than half of the cell population (Fig. 5b), but the effect was already evident when 
using 1 × EC50 (Fig. S2). The phenotype of these abnormal parasites appeared heterogeneous: along 
with 3K1N and 1K3N cells, trypanosomes with a much higher number of either K or N, or both, were 
observed. 
This experiment implies that, at least for a period, the S phase is not inhibited by S-MGBs and that, 
while exposed to 7, trypanosomes maintain their ability to synthesise new DNA. This was confirmed 
by an EdU assay, which allows monitoring of DNA synthesis by visualising the incorporation of the 
thymidine analogue 5-ethynyl-2´-deoxyuridine (EdU) into newly formed DNA (Fig. S3). Although a 
dose-dependent inhibition of DNA synthesis in T. b. brucei treated with 7 was observed within 8 h of 
incubation, this occurred only when using high concentrations of the compound (5 × EC50 and 10 × 
EC50) and the inhibition was much less pronounced than that caused by the eukaryotic nuclear DNA 
polymerase inhibitor aphidicolin (42) (26% and 40% inhibition for 5 × EC50 and 10 × EC50, 
respectively, versus 90% with aphidicolin) (Fig. S3).
It thus appears that during the first 12-24 hours of incubation at least, DNA synthesis continues, but 
cytokinesis is progressively affected, leading to apparent growth arrest; after this, further DNA 
synthesis may also be affected (cell cycle arrest), as the percentage of 1N1K cells remains largely 
unchanged between 24 and 48 h. The period leading into this seems to correspond to the incubation 
time before the cells are irreversibly committed to death, i.e. the cell cycle arrest is the point where the 
damage becomes irreversible. 
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S-MGBs-treated trypanosomes present with an abnormal phenotype. T. b. brucei parasites from 
the experiment described above often presented with nuclei abnormal in morphology, position and 
integrity and, in extreme cases, completely fragmented (Fig. 5c). The increase in the number of 
nuclei/nuclear fragments and kinetoplasts was accompanied by an increase in cell size and in the 
number of flagella, features typical of a block preventing cytokinesis (43). 
Transmission electron micrographs of 7-treated T. b. brucei parasites showed a number of cellular 
aberrations at 8 h of exposure, before the appearance of the conspicuous abnormal phenotype 
observed by light and fluorescence microscopy at longer time points. TEM revealed treated parasites 
with irregular, elongated nuclei (Fig. 5d panel I), and some with abnormal flagella lacking a 
paraflagellar rod (Fig. 5d panel II). Others revealed unusual cytoplasmic axonemes, enlarged rough 
endoplasmic reticulum (Fig. 5d panel III) and an increase in multi-vesicular bodies (Fig. 5d panel II) 
when compared to DMSO-treated control parasites. These results suggest that, upon treatment with 7, 
trypanosomes encounter problems with cytokinesis, mitosis and flagellar pocket biogenesis, 
consistent with the subsequent cell cycle defects observed, in particular the accumulation of multi-
nucleated and multi-flagellated cells.
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 Figure 5. S-MGBs affect cell division and cell cycle progression. a Growth inhibition curves of 
cultures of T. b. brucei (left) and T. congolense (right) continuously exposed to different doses of 7 
(mean ± SEM, n≥3). b Left: quantification of the proportion of different cell types (based on the 
nucleus -N- and kinetoplast -K- configuration) of T. b. brucei exposed to 7 (2 × EC50). Cells with 
1K1N are in G1 or S phase; the kinetoplast S phase starts before nuclear S phase and is shorter than 
the latter, resulting in 2K1N cells in G2/M phase; the nucleus then divides during mitosis, generating 
2K2N post-mitotic cells, which undergo cytokinesis. The values for the untreated sample refer to the 
12 h time point. Right: quantification of the proportion of different cell types over time; more than 
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200 cells were analysed per sample (mean ± SEM, n=3). c DAPI-stained and corresponding DIC 
images of treated T. b. brucei (2 × EC50 of 7) from the same experiment; bar = 10 µm. d 
Representative transmission electron microscopy images of T. b. brucei treated with 7 (2 × EC50, 8 h) 
(panels I-III), and with DMSO as a control (panel IV). N, nucleus; M, mitochondrion;  F, flagellum; 
PFR, paraflagellar rod; MVB, multivesicular bodies; ER, rough endoplasmic reticulum; *F, flagellum 
without paraflagellar rod; *Ax, cytoplasmic axoneme. The EC50 values used for these experiments 
refer to those presented for the wild type  in Table S2 and Table S3.
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Discussion and Conclusion
Structure-activity relationships of anti-trypanosomal S-MGBs. Antimicrobial MGBs are generally 
active if they can reach target DNA and bind to it, thereby disrupting DNA function (44, 45).  S-
MGBs show a relative lack of activity against Gram-negative bacteria compared with Gram-positive 
bacteria (46) apparently because they penetrate the Gram-negative membrane poorly if at all. Access 
to DNA is also important in mammalian cell toxicity. With the current state of knowledge it is not yet 
possible to design compounds with the required species selectivity for minor groove binders and it is 
necessary to proceed empirically. Fortunately, each trypanosome species studied here shows a similar 
S-MGB SAR, probably reflecting a similar mechanism of cellular uptake, from which selective 
activity of MGBs commonly arises (47).
The possibility of developing a single compound with potent activity against both T. congolense and 
T. vivax is examined in Figure 6a, which shows a modest general correlation. The best compounds in 
this regard, 14 and 15, being found towards the lower left hand corner. However, both are essentially 
equitoxic to L6 cells and T. congolense / T. vivax, and it is evident that selectivity must outweigh 
trypanocidal activity. Thus, high activity against both species together with an acceptable selectivity 
index to mammalian cells is required for further development of compounds beyond this initial study 
and Figure 6b allows all three parameters to be visualized (Figs. S4 and S5 show this data in two 
separate plots). From this analysis 11 is a better starting point for further development than more 
active compounds in their proximity in Figure 6a, based on their moderate toxicity to L6 cells. The 
even lower toxicities associated with the amidine-containing tail groups in compounds 7 and 8 are 
also clearly evident. This high pKa tail group is a major determinant in the physicochemical properties 
of the S-MGBs leading to compounds protonated at physiological pH and is expected to be 
particularly important with respect to cellular uptake, intracellular distribution and efflux (46). 
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Figure 6. S-MGBs SAR revealed. a Comparative activities against T. vivax and T. congolense. The 
compounds with best activity against both trypanosome species are found towards the lower left hand 
corner of the plot. b Same data as a, but with additional L6 cytotoxicity represented as bubble plot – 
the lower the EC50 against L6, the smaller the bubble.
Of the three compounds evaluated in vivo, 11 had the poorest selectivity index (64) when comparing 
the activity against T. congolense in vitro with the cytotoxicity against L6 cells. Both 7 and 8 had 
selectivity indices greater than 200 and, unlike 11, were able to elicit complete cure at non-toxic 
doses. 
Differentiating S-MGBs from other anti-trypanosomal MGBs. Our results on diminazene-resistant 
T. congolense strains gave no indication of cross-resistance with the diamidine class of compounds, 
which is a factor of crucial importance for the future development of the S-MGBs as trypanocidal 
agents for AAT. Although both groups of molecules target the minor groove of DNA, preferences for 
different sequences might result in non-overlapping activities, although both are believed to 
preferentially bind A/T-rich sequences. A more probable explanation for this lack of cross-resistance, 
however, is the separate MGB classes entering trypanosomes by different routes, i.e. the S-MGBs do 
not enter trypanosomes via the same transporters that take up diamidines. Indeed, we observed no 
differences in S-MGB activity when tested on T. b. brucei lines lacking either TbAT1/P2 or both 
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TbAT1/P2 and HAPT/AQP2 transporters. Moreover, T. congolense does not have a syntenic 
equivalent to TbAT1, and its P1-type purine nucleoside transporter TcoAT1, inaccurately reported as 
being equivalent to TbAT1, does not recognise diminazene as a substrate (32). The transporters for the 
phenanthridines, ethidium and isometamidium have not yet been identified but their accumulation 
appears to be a balance between uptake and efflux across the plasma membrane with the driving force 
being the mitochondrial membrane potential segregating the drug in the mitochondrion (39, 48).
Distamycin A, the prototype MGB, has well-known affinity for AT-rich regions of DNA. It binds to 
regions with 4 or 5 AT base pairs, altering the double helix conformation and interfering with the 
binding of nuclear proteins (49). Derivatives of distamycin A, such as S-MGBs, are likewise expected 
to have a direct or indirect action on nucleic acid functions and/or replication, resulting in their 
trypanocidal activity. Evidence here shows that S-MGBs do indeed concentrate in the kinetoplast and 
nucleus. This is different from what is seen with the diamidines, which accumulate predominantly in 
the mitochondrion and have high affinity for the kinetoplast DNA. This explains why the absence of 
an intact kinetoplast is not linked to resistance to the S-MGBs, ruling it out as a main target. This does 
not mean S-MGBs do no damage the kinetoplast; rather, they also target the nucleus and the 
uncharged compound of the series will likely achieve the highest concentration initially in the 
cytoplasm.
Interestingly, the fluorescent S-MGBs were detected in cellular compartments other than the nucleus 
and kinetoplast, although it is unclear whether this might contribute to their trypanocidal activity or 
only represents a storage sink for the compounds. The brightly stained vesicle observed in treated T. 
congolense cells could correspond to what Vickerman defined as the "sac of secretion" (50), later 
called the "digestive vacuole", which is part of the endocytic apparatus of this parasite (51). Further 
work is needed to clarify if this is linked to the mechanism of internalisation of S-MGBs but 
endocytosis after binding to surface proteins could indeed be a route of entry for these relatively large 
compounds, as is the case for suramin (52).
Our data, showing an obvious cell cycle defect after treatment, with parasites becoming unable to 
correctly complete cell division and accumulating supernumerary kinetoplasts and nuclei and 
displaying an apparent fragmentation of nuclear material, are consistent with targeting of nuclear 
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DNA. This phenotype becomes manifest after a period of 12 to 24 hours, when it appears that the 
parasites in G1 phase (1K1N) are no longer able to enter the cell cycle. The exact causes of the 
cytokinesis block are still unclear but the combined evidence from the cell cycle experiments and the 
cellular distribution of the S-MGBs point to a potential multi-factorial mechanism of action, which 
would further delay the onset of resistance.
Metabolomics identified a significant accumulation of pyrimidines, particularly deoxyuridine, after 8 
hours of treatment, hence supporting the hypothesis of S-MGBs interference with nucleic acids 
functions.  In trypanosomes deoxyuridine is part of the pyrimidine salvage pathway: it is converted to 
dUMP (also significantly accumulating in treated cells), which is then converted into dTMP and the 
nucleoside triphosphate TTP used for DNA synthesis. From our results we could speculate that dUMP 
could accumulate as a result of downregulation of thymidylate synthase activity when DNA synthesis 
slows down, an hypothesis consistent with the absence of an accumulation of thymidine nucleotides 
despite an accumulation of other deoxynucleotides (dCTP, dAMP). This could generate high levels of 
dUTP, and its misincorporation into DNA, with consequent DNA damage. Previous work in T. brucei 
procyclic form found that addition of exogenous thymidine could alter the dTTP/dUTP ratio, 
reverting the inhibition of dUTPase (deoxyuridine triphosphate nucleotidohydrolase), the enzyme that 
provides the substrate for the thymidylate synthase and responsible for keeping the intracellular levels 
of dUTP low (53). However, we could not rescue bloodstream T. brucei grown in medium lacking 
thymidine and treated with 7 after addition of 10-20 mM of thymidine (data not shown). 
Existing MGB drugs, such as diminazene, have been of enormous value for the treatment and control 
of trypanosomiasis since their introduction more than half a century ago, but are now failing as anti-
parasitic therapeutics due to the significant rise of resistance. This study has demonstrated both the 
excellent in vitro activity and in vivo cure of parasitaemia by S-MGBs that are structurally distinct 
from existing MGB-based drugs. Specifically, in an in vivo model of infection of T. congolense, cures 
were demonstrate with either two applications of 50 mg/kg of 7 or two applications of 10 mg/kg of 8. 
Moreover, S-MGBs have been shown to be unaffected by existing MGB-resistance mechanisms, both 
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in T. congolense and in T. b. brucei; in the latter this is due to a different mechanism of uptake in T. 
brucei. Furthermore, we found no indication of potential cross-resistance to the other class of 
veterinary trypanocides currently used in Africa: the phenanthridines isometamidium and ethidium. 
Finally, despite numerous efforts, selection of resistance to the S-MGBs in vitro proved unsuccessful, 
a result that could indicate a degree of refractoriness to resistance mechanisms of these compounds, 
likely linked to non-specific uptake and multifactorial trypanocidal actions. Together these 
observations provide proof of concept of S-MGBs as potential novel therapeutic agents for animal 
African trypanosomiasis.
Experimental Section
Trypanosomes and cell culture. Bloodstream form T. congolense strain IL3000 and derived 
diminazene-resistant lines were cultured at the University of Glasgow as described in (54), at 34 °C in 
a humidified, 5% CO2 environment, in MEM medium (Sigma-Aldrich) supplemented with 25 mM 
HEPES, 26 mM NaHCO3, 5.6 mM D-glucose, 1 mM sodium pyruvate, 40 µM adenosine, 100 µM 
hypoxanthine, 16.5 µM thymidine and 25 µM bathocuproinedisulfonic acid disodium salt. To this 
basal medium were added freshly prepared β-mercaptoethanol (0.0014% v/v), 1.6 mM glutamine, 100 
units/ml penicillin, 0.1 mg/ml streptomycin, 20% goat serum (Gibco) and 5% Serum Plus (SAFC 
Biosciences). Bloodstream form T. b. brucei wild type (strain Lister 427) and derived lines were 
cultured at 37 °C in a humidified, 5% CO2 environment in HMI-11 (Gibco), containing 10% FBS 
(Gibco). Kinetoplast-independent F1-L262P)-expressing trypanosomes were kindly provided by Dr 
Achim Schnaufer (University of Edinburgh) and grown in the presence of 2 µg/ml G418. The 
akinetoplastic version of L262P, L262P(AK), was obtained by exposure to 10 nM ethidium bromide 
for several passages. Loss of kinetoplast was verified by fluorescence microscopy of DAPI-stained 
cells. The origins of the trypanosome stocks (T. congolense IL3000 and STIB 736/IL1180 and T. 
vivax STIB 719/ILRAD 560 strains) and their respective culture media used at the Swiss TPH 
Institute, have been previously described in reference 37.
Generation of diminazene-resistant T. congolense lines. Bloodstream form T. congolense strain 
IL3000 was selected for diminazene resistance by subculturing cells in vitro in the continuous 
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presence of increasing concentration of diminazene. To enhance the chances of obtaining a resistant 
phenotype, some lines were mutagenized with 0.001% EMS for 90 min prior to selection with the 
drug. After two years, clones DimR (not mutagenized) and EMS MUT DimR (mutagenized with 
EMS) were generated, both growing in the presence of 800 nM diminazene, being 10- and 12-fold 
resistant, respectively relative to wild type.
In vitro and ex vivo trypanocidal activity and L6 toxicity. The initial S-MGBs library screen 
against T. congolense, T. vivax and L6 cells (data presented in Table 1) was performed at the Swiss 
TPH Institute. To determine the EC50 values for the two trypanosome species specific modifications 
of the Alamar Blue assay (55) and the 3H-hypoxanthine incorporation assay (56) were used, as 
previously described in (37). All experiments were performed in three independent assay runs for 
each compound.
To ascertain the cytotoxicity of each compound tested, the Alamar Blue assay (56) was followed, 
using an L6 (rat skeletal myoblast) cell line, but with minor modifications. The cell density was 
calculated using a Neubauer counting chamber and then diluted accordingly with culture medium, to 
obtain a seeding density of 2×104 cells/ml. The microtitre plates were then incubated overnight at 37 
ºC and 5% CO2, to enable the cells to adhere to the plates. The following day, the test compounds 
were added to the plates, using a three-fold serial dilution step across each plate, before being placed 
back into the incubator for 69 h under the same conditions. Thereafter, the plates were removed from 
the incubator and 10 µl of resazurin dye were placed into each well. The plates were incubated for a 
further 3 h, under the same conditions. After a total of 72 h incubation, the plates were removed and 
read using a fluorescence reader (SpectraMax, Gemini XS, Bucher Biotec, Basel, Switzerland) at an 
excitation wavelength of 536 nm and an emission wavelength of 588 nm. The EC50 values were 
determined using SOFTmax Pro 5.2 analysis software.
A modified Alamar Blue assay protocol was used to study S-MGBs cross-resistance in diminazene 
resistant T. congolense and T. b. brucei at the University of Glasgow. T. b. brucei (2×104 cell/ml) or 
T. congolense (2.5×105 cell/ml) cells were seeded into 96-well plates containing serial 2-fold dilutions 
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of test compounds. After 48 h incubation at (37 °C for T. b. brucei and 34 °C for T. congolense; 5% 
CO2), 20 µl of resazurin dye solution (0.49 mM in PBS, Sigma-Aldrich) was added, and cells were 
incubated for a further 24 h before fluorescence was determined. Akinetoplastic T. b. brucei lines 
(ISMR1 and L262P (AK)) were incubated with test compounds for 69 h, before addition of 10 µl of 
resazurin dye and readout after a further 3 h incubation. Resazurin reduction was measured with a 
fluorimeter (FLUOstar Optima, BMG Labtech) using 544 nm excitation and 590 nm emission 
wavelengths. Data were plotted to an equation for a sigmoid curve with variable slope in GraphPad 
Prism 5 software. All experiments were carried out on at least three independent occasions. 
In vivo trypanocidal activity. Pathogen-free (SPF) NMRI female mice (21-23 g) were used for all in 
vivo mouse trials within this study. Mice were housed in standard Macrolon Type II cages and were 
kept at a room temperature of 22 ºC and a relative humidity of 60-70%, receiving pelleted food and 
water ad libitum. All in vivo mouse trials were conducted in accordance with the regulations and 
guidelines set out by the Swiss Federal Veterinary Office, under License Number RB-739. For the in 
vivo mouse trials, a 50 mg/kg stock solution was prepared for each of the S-MGB test compounds, 
dissolved in sterile distilled water and containing no more than 10% DMSO. From these stock 
solutions, further dilutions were made depending on the dose being tested. All stock solutions and 
dilutions were made fresh on the day of administration and for each separate mouse trial. Mice were 
randomly selected and arranged into groups of four, before being independently infected 
intraperitoneally (i.p.) with 105 parasites in 0.25 ml of (6:4) phosphate buffered saline with glucose 
(PSG), using a drug-sensitive strain of T. congolense (STIB 736/IL1180). Infection of all in vivo 
mouse trials was performed from stabilated infected blood, stored frozen in liquid nitrogen, held 
within the cryobank of the Swiss TPH Institute. For all T. congolense mouse trials, a parasitaemia of 
106 per ml blood was allowed to develop over 7 days, before compound treatment was administered 
(i.p.) on days 7 and 8 post infection (p.i.) (for 2 application regimens, 24 h apart) or days 7 to 10 p.i. 
(for 4 application regimens, 24 h apart). For single bolus dose applications, compound treatment (i.p.) 
was initiated on day 7 p.i. only. Subsequently, parasitaemia in mice was monitored using a tail blood 
examination technique, until day 60 post treatment to check for any possible relapses. Parasitaemia 
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was checked twice a week for the first 30 days and then once per week thereafter. At the end of the in 
vivo mouse trials, any surviving and aparasitaemic mice were considered cured. Untreated control 
mice survive, on average, 11 days p.i. using this infection protocol.
Fluorescence microscopy. T. congolense cells (5×105 cells/ml) were treated with highly fluorescent 9 
or 16 (2 × EC50) for 2 - 48 h at 34 °C in a humidified 5% CO2 atmosphere. For DAPI co-localisation, 
20 µM of DAPI in water solution was added to the cultures 15 min before slide preparation. At set 
time points, cells were washed in PBS, and an aliquot of parasites was mixed with an equal volume of 
2% w/v low melting point agarose (Sigma-Aldrich) and spread onto a slide by addition of a coverslip. 
Slides were viewed using a Zeiss Axioplan 2 Imaging epifluorescence microscope, equipped with a 
digital CCD camera (Hammatsu Photonics) and a PlanNEUFLUAR 100× oil-immersion NA 1.4 
objective (Carl Zeiss). Standard  FITC, GFP , DsRed and DAPI filters were used, and images were 
acquired using Volocity imaging software (Improvision). Images were merged using GIMP 2.10.4 
software to overlay for co-localisation. 
Time-to-kill assay. Killing kinetics curves for 7 were obtained by continuously exposing T. b. brucei 
(2×104 cell/ml) or T. congolense (1.25×105 cell/ml) to different doses of the compound. Cell densities 
were counted at set timepoints using a Neubauer haemocytometer. Three independent measurements 
were obtained for each condition. 
Reversibility of trypanocidal effect. To determine the time required for 7 to cause irreversible 
effects on trypanosomes, an adaptation of a protocol published by Kaminsky et al. (57) was adopted. 
T. b. brucei (2×104 cell/ml) and T. congolense (2.5×105 cell/ml) were exposed to different doses of the 
compound, for set periods, under standard culture conditions. A pulse timepoint, where parasites were 
exposed to the compound and washed immediately after, was also included. Drug concentrations 
sufficient to kill at least 99.9% of cells determined from the EC50 curves were chosen for this 
experiment, but these had to be further increased to 10 and 20 fold EC50 to obtain cidal effect on T. b. 
brucei. At the designated times, cells were collected and washed twice in ice-cold medium to remove 
test compound. Parasites were finally resuspended in 1 ml of warm medium and cultivated in 24-well 
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plates. Parasites were then monitored daily for 15 days by light microscopy, to assess their ability to 
recover from transient exposure to the compound. All sets of conditions were assessed in triplicate. 
The veterinary drug diminazene was examined in parallel for comparison.
EdU incorporation assay. Direct measurement of DNA synthesis was performed using the Click-iT® 
EdU assay (Thermo Fisher Scientific) following manufacturers' instructions with some modifications. 
T. b. brucei (5 × 105 cell/ml), maintained in thymidine-free HMI-11 medium, were seeded in 24-well 
plates and treated with different concentrations of 7, for 8 h under standard culture conditions. 5-
ethynyl-2´-deoxyuridine (EdU) was added at a final concentration of 150 µM to each well, 4 h before 
the end of the treatment with test compound. Cells were then placed onto each well of a 12-spot 
microscope slide (Thermo Scientific) coated with poly-L-lysine, and allowed to adhere for 15 min at 
room temperature. After careful removal of the medium, trypanosomes were fixed with a 3.7% 
formaldehyde solution. After fixative removal, cells were washed with 1× PBS and then 
permeabilised for 30 min with a 0.1% Triton X-100 solution in 1× PBS. This was removed and the 
cells were washed twice with 1× PBS prior to the addition of 25 µl of a freshly prepared Click-iT® 
EdU detection mix (Thermo Fisher Scientific), containing the fluorophore Alexa Fluor 555 Azide. 
The mix was incubated with the cells for 1 h at room temperature, in a humidity chamber, protected 
from light. At the end of the incubation time, cells were washed 6 times with 1× PBS and finally 
counterstained with 4 µM DAPI and covered with a coverslip. Incorporation of the nucleoside 
analogue of thymidine, EdU, into newly synthesized DNA was visualised using a Zeiss Axioplan 2 
imaging epifluorescence microscope, equipped with a digital CCD camera (Hammatsu Photonics) and 
a PlanNEUFLUAR 100× oil-immersion NA 1.4 objective (Carl Zeiss) using RHOD filter set. DMSO 
samples were prepared as negative controls, and aphidicolin (an inhibitor of eukaryotic nuclear DNA 
replication) (Sigma-Aldrich) was used as positive control at a dose of 1 µg/ml. All conditions were 
assessed in at least four independent occasions. 
Cell cycle analysis. Nuclei/kinetoplast (N/K) configurations of 7-treated T. b. brucei were monitored 
to assess effects on cell cycle progression. Trypanosomes (2×104 cell/ml) were treated either with 
different doses of test compound or DMSO as negative control and kept under standard culture 
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conditions in 24-well plates. At set timepoints (12, 24, 48 and 72 h), trypanosomes were collected, 
applied to a slide and allowed to dry. Slides were fixed overnight in cold methanol and kept at 4 °C 
after drying. Fixed cells were then rehydrated by adding 1-2 ml of PBS and, after eliminating the 
excess buffer, stained with 4 µM DAPI. A Zeiss Axioplan 2 Imaging epifluorescence microscope, 
equipped with a digital CCD camera (Hammatsu Photonics) and a PlanNEUFLUAR 100× oil-
immersion NA 1.4 objective (Carl Zeiss) was used to view cells, using a standard DAPI filter set. 
Volocity imaging software (Improvision) was used for image acquisition. For each condition, the N/K 
configuration of at least 200 cells was recorded. Trypanosomes with configurations 3K1N, 1K3N (in 
which at least the N or the K had undergone two rounds of division in absence of cytokinesis), as well 
as cells with highly fragmented DNA-containing organelles were all included in the MKMN category. 
The experiment was carried out on three independent occasions.
Metabolomics analysis. Following treatment with test compound 7 at 2 × EC50 for 8 h under standard 
culture conditions (or to a corresponding volume of DMSO for the negative controls), T. b. brucei 
metabolites were extracted for untargeted metabolomics analysis. For each sample, 1 × 108 cells were 
collected and rapidly cooled to 4 °C by submersion of the tube in a dry ice-ethanol bath, to quench 
metabolism and denature proteins. Samples were kept at this temperature for all of the subsequent 
steps. Following centrifugation (1250 × g, 10 min), the supernatant was removed and the cell pellet 
was washed in 1 × PBS. The PBS was then removed and the cells lysed by resuspending in 200 µl of 
extraction solvent (chloroform:methanol:water 1:3:1). Metabolite extraction was obtained by vigorous 
shaking for 1 h at 4 °C. Extract mixture was then centrifuged at maximum speed and the supernatant 
collected and frozen at -80 °C under argon until LC-MS analysis. Four biological replicates were 
prepared for each condition.
Samples were analysed at the Glasgow Polyomics Metabolomics Facility using an Exactive Orbitrap 
mass spectrometer (Thermo Fisher) in both positive and negative modes (switching mode) and 
coupled to a HPLC system (Dionex) with a ZIC-pHILIC column (Merck SeQuant), as described 
before. Exactive data were acquired as previously described (58). Untargeted peak-picking and peak 
matching from raw LC-MS data were obtained using XCMS and mzMatch respectively. Metabolite 
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identification and relative quantitation was performed using the IDEOM interface (59), by matching 
accurate masses and retention times of authentic standards or, when standards were not available, by 
using predicted retention times. The putative metabolite list obtained by IDEOM was manually 
checked and filtered based on peak intensity and shape. Statistical analysis of the resulting list was 
performed using MetaboAnalyst 3.0 following log transformation of the data. Fragmentation patterns 
were integrated in the analysis using the Polyomics integrated Metabolomics Pipeline (PiMP) (60).
Transmission electron microscopy. T. b. brucei parasites (1 × 106 cells/ml) were treated with 7 (2 × 
EC50) for 8 h. Parasites were then collected, washed once in 1× PBS, and resuspended in fixative 
(2.5% glutaraldehyde plus 4% paraformaldehyde in 0.1 M PIPES, pH 7.3). After washing in 0.1 M 
sodium cacodylate buffer, cells were post-fixed in 1% osmium tetroxide for 1 h in the dark, washed in 
distilled water and stained with 0.5% aqueous uranyl acetate solution for 30 min in the dark. Parasites 
were then washed in distilled water and dehydrated in acetone solutions (30, 50, 70, 90, 100%). Cell 
were then embedded in epoxy resin (TAAB Laboratories Equipment Ltd). Ultrathin sections (50 nm) 
were sectioned using a Leica EM UC7 ultramicrotome, collected in Formvar-coated grids and 
visualised on a Jeol 1200 transmission electron microscope operating at 80 kV.
Compound synthesis. The details of previously published compounds can be found in the 
Supplementary Information. The following describes the synthesis of novel compounds.
Chemical reagents were obtained from Aldrich Chemical (Saint Louis, Missouri), Acros Organics, 
abcr GmBh (Karlsruhe, Germany), ACB Blocks (Toronto, Canada) and Chembridge, and were used 
without further purification. 1H spectra were measured on a Bruker DPX-400 MHz 
spectrometer with chemical shifts given in ppm (δ-values), relative to proton and carbon 
traces in solvent. Coupling constants are reported in Hz. 13C NMR are not reported due to 
synthesis of insufficient material and our experience of 13C NMR spectra being uninformative 
in S-MGB characterisation due to significantly overlapping signals. IR spectra were recorded 
on a Perkin Elmer, 1 FT-IR spectrometer. Mass spectra were obtained on a Jeol JMS AX505. 
Anhydrous solvents were obtained from a Puresolv purification system, from Innovative 
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Technologies, or purchased as such from Aldrich. Chromatography was carried out using 
200-400 mesh silica gels, or using reverse-phase HPLC on a waters system using a C18 Luna 
column. All final MGBs were of  >95% purity as determined by HPLC.
HPLC method used for the purification of final MGBs:
Time (mins) Flow rate (mL/min) %Water (0.1%TFA) %Acetonitrile (0.1%TFA)
0 6 90 10
25 6 60 40
35 6 50 50
40 6 30 70
44 6 90 10
5-{[(5-{[(5-{[(3-amino-3-iminiopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-
yl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)amino]carbonyl}-2-[(E)-2-(4-
methoxyphenyl)ethenyl]pyridinium bis(trifluoroacetate) 7
N-(5-{[(3-Amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-1-methyl-4-
nitro-1H-pyrrole-2-carboxamide (61) (30 mg, 0.083 mmol) was dissolved in MeOH (3 mL) 
to which was added Pd/C-10 % (30 mg) and this was subjected to hydrogenation for 2 h at 
atmospheric pressure. After this, the reaction mixture was filtered through keisulghur and the 
solvent removed by rotary evaporation. The resulting residue was dissolved in dry DMF (1 
mL) and to this was added 6-[(E)-2-(4-hydroxyphenyl)ethenyl]nicotinic acid (17) (21 mg, 
0.083 mmol) and HBTU (64 mg, 0.17 mmol). The reaction mixture was left to stir overnight 
at room temperature and subjected to HPLC purification directly to yield the desired material 
as an off-white solid (21 mg, 32 %).
IR: 3295, 3094, 2935, 1677, 1655, 1640, 1612, 1578, 1558, 1543, 1530, 1472, 1433, 1408, 
1386, 1261, 1196, 1183, 1134, 1064, 1013, 965 cm-1
δH NMR (DMSO-d6): 10.35 (1H, s), 9.95 (1H, s), 9.26 (1H, d, J = 2.0), 8.89 (2H, s), 8.54 
(1H, m),  8.43 (2H, s), 8.19 (1H, m), 7.99-8.03 (4H, m), 7.59-7.82 (6H, m), 7.34 (1H, d, J = 
Page 32 of 51
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1.5), 7.18 (1H, d, J = 1.5), 7.12 (1H, d, J = 1.5), 6.97 (1H, d, J = 1.5), 3.88 (3H, s), 3.82 (6H, 
s), 3.48-3.51 (2H, m), 2.58-2.62 (2H, m).
HR-MS-FAB: Found 569.2618 calculated for C30H33O4N8+ (M+H) 569.2619.
1-amino-3-({[4-({[4-({4-[(E)-2-(3-methoxyphenyl)ethenyl]benzoyl}amino)-1-methyl-1H-
pyrrol-2-yl]carbonyl}amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-
propaniminium trifluoroacetate 8
N-(5-{[(3-Amino-3-iminopropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-yl)-1-methyl-4-
nitro-1H-pyrrole-2-carboxamide (61) (30 mg, 0.083 mmol) was dissolved in MeOH (3 mL) 
to which was added Pd/C-10 % (30 mg) and this was subjected to hydrogenation for 2 h at 
atmospheric pressure. After this, the reaction mixture was filtered through keisulghur and the 
solvent removed by rotary evaporation. The resulting residue was dissolved in dry DMF (1 
mL) and to this was added 4-[(E)-2-(3-methoxyphenyl)ethenyl]benzoic acid (17) (21 mg, 
0.083 mmol) and HBTU (64 mg, 0.17 mmol). The reaction mixture was left to stir overnight 
at room temperature and subjected to HPLC purification directly to yield the desired material 
as an off-white solid (22 mg, 39 %).
IR: 3295, 3068, 2948, 2824, 1703, 1673, 1655, 1632, 1614, 1582, 1561, 1546, 1532, 1513, 
1502, 1489, 1470, 1436, 1403, 1390, 1276, 1198, 1174, 1121, 1051, 1008 cm-1
δH NMR (DMSO-d6): 10.31 (1H, s), 9.94 (1H, s), 8.89 (2H, s), 8.48 (2H, s), 8.19 (1H, t, J = 
5.5), 7.95 (2H, d, J = 8.5), 7.73 (2H, d, J = 8.5), 7.29-8.37 (4H, m), 7.21-7.23 (2H, m), 7.18 
(1H, d, J = 1.5), 7.10 (1H, d, J = 1.5), 6.95 (1H, d, J = 1.5), 6.88 (1H, m), 3.87 (3H, s), 3.81 
(3H, s), 3.80 (3H, s), 3.48-3.51 (2H, m), 2.58-2.62 (2H, m).
HR-MS-FAB: Found 568.2672 calculated for C31H34O4N7+ (M+H) 568.2667.
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N-[5-({[5-({[2-(Dimethylamino)ethyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-
yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-6-{(E)-2-[4-
(dimethylamino)phenyl]ethenyl}nicotinamide 9
N-[2-(Dimethylamino)ethyl]-1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-
yl)carbonyl]amino}-1H-pyrrole-2-carboxamide (62) (0.160 g, 0.147 mmol) was dissolved in 
methanol (25 mL) to which Pd/C-10% (35 mg) was added at room temperature with stirring 
under nitrogen. The reaction mixture was hydrogenated at room temperature and atmospheric 
pressure for 2h. The catalyst was removed over Kieselguhr and methanol was removed under 
reduced pressure to give the amine which was dissolved in dry DMF (2 mL). 6-{(E)-2-[4-
(dimethylamino)phenyl]ethenyl}nicotinic acid (20) (39 mg, 0.147 mmol) and HBTU (102 
mg, 0.147 mmol) were added with stirring at room temperature. The reaction mixture was 
heated at 55oC for 24h. HPLC purification of the reaction mixture gave the required product 
as a red solid material (44 mg, 52%) with no distinct melting point.
IR: 720, 804, 1128, 1175, 1287, 1366, 1435, 1528, 1576, 1668 cm-1
δH NMR (DMSO-d6): 10.45 (1H, s), 9.98 (1H, s), 9.27 (1H, br), 9.04 (1H, s), 8.25 (1H, dd, J 
= 2.85, 13.0), 8.19 (1H, t, J = 8.9), 7.72 (1H, d, J = 16.0), 7.64 (1H, d, J = 8.3), 7.54 (2H, d, J 
= 8.9), 7.34 (1H, d, J = 1.5), 7.21 (1H, d, J = 1.5), 7.10-7.15 (2H, m), 7.01 (1H, d, J = 1.5), 
6.76 (2H, d, J = 8.9), 3.89 (3H, s), 3.84 (3H, s), 3.52 (2H, q, J = 6.0), 3.23 (2H, q, J = 6.0), 
2.99 (6H, s), 2.85 (6H, m).
HR-MS-FAB: found: 583.3144 calculated for C32H38N8O3 583.3145
N-[2-(Dimethylamino)ethyl]-4-({[4-({4-[(E)-2-(3-
methoxyphenyl)ethenyl]benzoyl}amino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-
methyl-1H-pyrrole-2-carboxamide 10
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N-[2-(Dimethylamino)ethyl]-1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-
yl)carbonyl]amino}-1H-pyrrole-2-carboxamide (62) (0.160 g, 0.147 mmol) was dissolved in 
methanol (25 mL) to which Pd/C-10% (35 mg) was added at room temperature with stirring 
under nitrogen. The reaction mixture was hydrogenated at room temperature and atmospheric 
pressure for 2h. The catalyst was removed over Kieselguhr and methanol was removed under 
reduced pressure to give the amine which was dissolved in dry DMF (2 mL). 4-[(E)-2-(3-
methoxyphenyl)ethenyl]benzoic acid (17) (38 mg, 0.147 mmol) and HBTU (102 mg, 0.147 
mmol) were added with stirring at room temperature. The reaction mixture was heated at 
55oC for 24h. HPLC purification of the reaction mixture gave the required product as pale 
yellow solid material (30 mg, 36%) with no distinct melting point.
IR: 689, 777, 976, 1134, 1165, 1198, 1262, 1402, 1433, 1464, 1514, 1580, 1641 cm-1
δH NMR (DMSO-d6): 10.32 (1H, s), 9.96 (1H, s), 9.28 (1H, br), 8.183 (1H, t, J = 5.6), 7.96 
(2H, d, J = 8.4), 7.73 (2H, d, J = 8.4), 7.28-7.40 (4H, m), 7.18-7.22 (3H, m), 7.11 (1H, d, J = 
1.5), 7.00 (1H, d, J = 1.5), 6.88 (1H, dd, J = 3.7, J = 1.5), 3.87 (3H, s), 3.83 (3H, s), 3.81 
(3H, s), 3.51 (2H, q, J = 6.0), 3.21 (2H, q, J = 6.0), 2.84 (6H, m).
HR-MS-FAB: found: 569.2880 calculated for C32H36N6O4 569.2876
N-[2-(Dimethylamino)ethyl]-1-methyl-4-({[1-methyl-4-({4-[(E)-2-(3-
quinolinyl)ethenyl]benzoyl}amino)-1H-pyrrol-2-yl]carbonyl}amino)-1H-pyrrole-2-
carboxamide 11
N-[2-(Dimethylamino)ethyl]-1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-
yl)carbonyl]amino}-1H-pyrrole-2-carboxamide (62) (0.160 g, 0.147 mmol) was dissolved in 
methanol (25 mL) to which Pd/C-10% (35 mg) was added at room temperature with stirring 
under nitrogen. The reaction mixture was hydrogenated at room temperature and atmospheric 
pressure for 2h. The catalyst was removed over Kieselguhr and methanol was removed under 
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reduced pressure to give the amine which was dissolved in dry DMF (2 mL). 4-[(E)-2-(3-
quinolinyl)ethenyl]benzoic acid (17) (41 mg, 0.147 mmol) and HBTU (102 mg, 0.147 mmol) 
were added with stirring at room temperature. The reaction mixture was left stirring at room 
temperature for 24h. HPLC purification of the reaction mixture gave the required product as 
yellow solid material (14 mg, 14%) with no distinct melting point.
IR: 720, 831, 972, 1061, 1128, 1196, 1267, 1414, 1431, 1495, 1539, 1624, 1674 cm-1
δH NMR (DMSO-d6): 10.35 (1H, s), 9.97 (1H, s), 9.26 (2H, b), 8.56 (1H, d, J = 2.0), 8.18 
(1H, t, J = 6.0), 7.98-8.04 (4H, m), 7.81 (2H, d, J = 9.0), 7.76 (1H, t, J = 6.5), 7.6-7.7 (3H, 
m), 7.33 (1H, d, J = 2.0), 7.20 (1H, d, J = 2.0), 7.12 (1H, d, J = 2.0), 7.00 (1H, d, J = 2.0), 
3.88 (3H, s), 3.83 (3H, s), 3.51 (2H, q, J = 6.0), 3.23 (2H, q, J = 6.0), 2.84 (6H, m).
HR-MS-FAB: found: 590.2882 calculated for C34H35N7O3 590.2880
5,6-Dichloro-N-[5-({[5-({[4-({[3-(dimethylamino)propyl]amino}carbonyl)-5-isopropyl-
1,3-thiazol-2-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-
1H-pyrrol-3-yl]nicotinamide 17
N-[3-(Dimethylamino)propyl]-5-isopropyl-2-{[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-
yl)carbonyl]amino}-1H-pyrrol-2-yl)carbonyl]amino}-1,3-thiazole-4-carboxamide (90 mg, 
0.165 mmol) was dissolved in methanol (25), then it was cooled to 0oC and Pd/C-10% (82 
mg) was added portionwise under N2 with stirring. The reaction mixture was hydrogenated at 
room temperature and atmospheric pressure for 6h. The catalyst was removed over 
Kieselguhr and the solvent was removed under reduced pressure. 5,6-Dichloronicotinic acid 
(32 mg, 0.165 mmol) was dissolved in thionyl chloride (2 mL) and heated under reflux for 
2h. Excess thionyl chloride was removed under reduced pressure and the residue was 
dissolved in dry DCM (5 mL). The amine was dissolved in dry DCM (5mL) to which NMM 
(0.5 mL) was added followed by the acid chloride solution. The stirring was continued at 
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room temperature overnight. The volatile material was removed under reduced pressure and 
the crude product was purified by HPLC. Fractions containing the required material were 
collected and freeze dried to give the pure product as light brown solid (66 mg, 50%) with no 
distinct melting point. 
IR: 1660, 1548, 1466, 1284, 1201, 1129, 774, 721 cm-1. 
δH NMR (DMSO-d6):  12.05(1H, s), 10.68(1H, s), 10.11(1H, s), 9.32(1H, br), 8.89(1H, d, 
J=2.4Hz), 8.59(1H, d, J=2.5Hz), 7.96(1H, t, unresolved), 7.45(1H, d, J=1.6Hz), 7.40(1H, d, 
J=1.6Hz), 7.36(1H, d, J=1.6Hz), 7.13(1H, d, J=1.6Hz), 4.20(1H, quintet, J=6.8Hz), 3.89(6H, 
s), 3.35(2H, q, J=6.4Hz), 3.06(2H, m), 2.79(6H, d, J=4.7Hz), 1.87(2H, q, unresolved), 
1.29(6H, d, J=6.8Hz). 
HR-MS-FAB: found: 688.2017 calculated for C30H36N9O4S35Cl2 688.1988.
4-(Ethanimidoylamino)-1-methyl-N-[1-methyl-5-({[1-methyl-5-({[2-(4-
morpholinyl)ethyl]amino}carbonyl)-1H-pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-
1H-pyrrole-2-carboxamide 18
1-Methyl-N-[1-methyl-5-({[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-
pyrrol-3-yl]amino}carbonyl)-1H-pyrrol-3-yl]-4-nitro-1H-pyrrole-2-carboxamide (56 mg, 
0.106 mmol) was dissolved in methanol (25 mL) to which Pd/C-10% (29 mg) was added at 
0oC under N2 with stirring. The reaction mixture was hydrogenated for 6h at room 
temperature and atmospheric pressure. The catalyst was removed over Kieselguhr. To the 
methanolic solution of the amine, methyl ethanimidothioate hydroiodide (23 mg, 0.106 
mmol) was added at room temperature with stirring. The solution was left standing at room 
temperature for 48h. HPLC purification gave the product as white solid (32 mg, 39%) with 
no distinct melting point. 
IR: 1665, 1550, 1290, 1200, 1131 cm.-1 
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δH NMR (DMSO-d6): 10.84(1H, s), 9.97(1H, s), 9.93(1H, s), 9.72(1H, br), 9.42(1H, s), 
8.35(1H, s), 8.22(1H, s), 7.24(1H, d, J=1.7Hz), 7.19(1H, d, J=1.7Hz), 7.16(1H, d, J=1.7Hz), 
7.06(1H, d, J=1.7Hz), 5.99(1H, d, J=1.7Hz), 6.92(1H, d, J=1.7Hz), 3.98(2H, m), 3.91(3H, s), 
3.85(3H, s), 3.82(3H, s), 3.71-3.13(10H, m), 2.29(3H, s). 
HR-MS-FAB: found: 538.2881 calculated for C26H36N9O4 538.2890
N-[5-({[5-({[5-Isopropyl-4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1,3-thiazol-2-
yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-pyrrol-3-
yl]-3-isoquinolinecarboxamide 19
5-isopropyl-2-{[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrol-
2-yl)carbonyl]amino}-N-[2-(4-morpholinyl)ethyl]-1,3-thiazole-4-carboxamide (38 mg, 0.066 
mmol) was dissolved in methanol (25 mL) to which Pd/C-10% (40 mg) was added at 0oC 
under N2 with stirring. The reaction mixture was hydrogenated for 5h at room temperature 
and atmospheric pressure. The catalyst was removed over Kieselguhr. Methanol was 
removed under reduced pressure at 50oC and the amine so formed was dissolved in dry DMF 
(1 mL) to which NMM (40 μL) was added at room temperature with stirring followed by 3-
isoquinolinecarboxylic acid (12 mg, 0.070) and HBTU (52 mg, 0.140 mmol). The stirring 
was continued at room temperature overnight. The product was obtained as white solid (25 
mg, 36%) with no distinct melting point (after the purification by HPLC). 
IR: 1662, 1545, 1276, 1200 cm.-1 
δH NMR (DMSO-d6): 12.00(1H, s), 10.83(1H, s), 10.08(1H, s), 9.60(1H, br), 9.45(1H, s), 
8.64(1H, s), 8.30(1H, d, J=7.7Hz), 8.24(1H, d, J=7.7Hz), 8.10(1H, t, J=6.0Hz), 7.92(1H, dt, 
J=1.6Hz & 7.0Hz), 7.85(1H, dt, J=1.6Hz & 7.0Hz), 7.45(2H, d, J=1.7Hz), 7.41(1H, d, 
J=1.7Hz), 7.33(1H, d, J=1.7Hz), 4.20(1H, septet, J=6.9Hz), 3.99-3.93(2H, m), 3.905(3H, s), 
3.901(3H, s), 3.66-3.12(10H, m), 1.30(6H, d, J=6.9Hz). 
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HR-MS-FAB: found: 698.2867 calculated for C35H40O5N9S 698.2873.
4-[(4-{(E)-2-[2-(1H-1,2,3-Benzotriazol-1-yloxy)-3-quinolinyl]ethenyl}benzoyl)amino]-1-
methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-pyrrol-3-yl]-1H-
pyrrole-2-carboxamide 20
1-Methyl-N-[1-methyl-5-({[2-(4-morpholinyl)ethyl]amino}carbonyl)-1H-pyrrol-3-yl]-4-
nitro-1H-pyrrole-2-carboxamide (50 mg, 0.124 mmol) was dissolved in methanol (25 mL) to 
which was added Pd/C-10% (50 mg) at 0oC (under N2) with stirring. The reaction mixture 
was hydrogenated for 3h at room temperature and atmospheric pressure. The catalyst was 
removed over Kieselguhr and the methanol was removed under reduced pressure. The amine 
so formed was dissolved in dry DMF (1 mL). To the amine solution the following were 
added: 4-[(E)-2-(2-chloro-3-quinolinyl)ethenyl]benzoic acid (38 mg, 0.124 mmol) and HBTU 
(94 mg, 0.248 mmol) and the reaction mixture was kept stirring overnight. The product was 
purified by HPLC (no work up required) to give the required product as a yellow solid after 
freeze drying (19 mg, 17%) with no distinct melting point.
IR: 1681, 1642, 1581, 1540, 1464, 1435, 1404, 1266, 1202, 1134 cm.-1 
δH NMR (DMSO-d6): 10.39(1H, s), 9.97(1H, s), 9.55(1H, s), 9.03(1H, s), 8.24(2H, d, 
J=8.3Hz), 8.08-8.02(3H, m), 7.93-7.89(2H, m), 7.85-7.77(3H, m), 7.66-7.54(4H, m), 
7.37(1H, d, J=7.8Hz), 7.34(1H, d, J=1.6Hz), 7.21(1H, d, J=1.6Hz), 7.14(1H, d, J=1.6Hz), 
7.01(1H, d, J=1.6Hz), 4.02(2H, m), 3.88(3H, s), 3.86(3H, s), 3.69-3.53(6H, m), 3.27-
3.14(4H, m). 
HR-MS-FAB: Found: 765.3267 calculated for C42H41N10O5 765.3261.
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2-[({4-[(4-{(E)-2-[2-(1H-1,2,3-benzotriazol-1-yloxy)-3-
quinolinyl]ethenyl}benzoyl)amino]-1-methyl-1H-pyrrol-2-yl}carbonyl)amino]-5-
isopentyl-N-[2-(4-morpholinyl)ethyl]-1,3-thiazole-4-carboxamide 21
5-Isopentyl-2-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-N-[2-(4-
morpholinyl)ethyl]-1,3-thiazole-4-carboxamide: (80 mg, 0.167 mmol) was dissolved in 
methanol (25 mL) to which was added Pd/C-10% (60 mg) at 0oC (under N2) with stirring. 
The reaction mixture was hydrogenated for 4h at room temperature and atmospheric pressure. 
The catalyst was removed over Kieselguhr and the methanol was removed under reduced 
pressure. The amine so formed was dissolved in dry DMF (2 mL). To the amine solution the 
following were added: 4-[(E)-2-(2-chloro-3-quinolinyl)ethenyl]benzoic acid (46 mg, 0.167 
mmol) and HBTU (126 mg, 0.334 mmol) and the reaction mixture was kept stirring at room 
temperature overnight. The product was purified by HPLC (no work up required) to give the 
required product as a yellow solid after freeze drying (19 mg, 12%) with no distinct melting 
point.
IR: 1663, 1551, 1502, 1401, 1288, 1202, 1137, 778, 750 cm.-1 
δH NMR (DMSO-d6): 12.09(1H, s), 10.49(1H, s), 9.68(1H, br), 9.03(1H, s), 8.93(1H, s), 
8.23(1H, d, J=8.4Hz), 8.09-7.95(6H, m), 7.90-7.77(6H, m), 7.70(1H, t, J=7.0Hz), 7.65-
7.57(4H, m), 7.55(1H, d, J=1.6Hz), 7.46(1H, d, J=1.6Hz), 7.37(1H, d, J=9.1Hz), 12.08(1H, 
s), 10.49(1H, s), 9.72(1H, br), 9.03(1H, s), 8.24(1H, d, J=8.4Hz), 8.08-7.99(3H, m), 7.94-
7.88(1H, m), 7.85-7.79(2H, m), 7.66-7.56(3H, m), 7.54(1H, d, J=1.6Hz), 7.46(1H, d, 
J=1.6Hz), 7.37(1H, d, J=7.9Hz), 4.02(2H, m), 3.93(3H, s), 3.70-3.54(6H, m), 3.31-3.15(6H, 
m), 1.64-1.51(3H, m), 0.93(6H, d, J=6.3Hz). 
HR-MS-FAB: Found: 839.3455 calculated for C45H47O5N10S 839.3452.
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S-MGB Strathclyde-minor groove binder
MKMN multiple kinetoplasts and nuclei
EdU 5-ethynyl-2´-deoxyuridine 
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